The Department of Defense (DoD) offers the Therapeutic Idea Award for novel Amyotrophic Lateral Sclerosis (ALS) treatment. This grant supports early-stage, conceptually innovative, high-risk/high-reward research aiming to yield impactful data and new investigative avenues for ALS therapeutics. The program seeks groundbreaking scientific inquiries that could lead to critical discoveries or major advancements in ALS treatment. Projects must feature a well-formulated, testable hypothesis underpinned by strong scientific rationale. This award champions pioneering work with the potential for transformative impact on ALS patient care and scientific understanding.
Opportunity ID: 89013
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-11-ALSRP-TIA |
| Funding Opportunity Title: | DoD Amyotrophic Lateral Sclerosis Therapeutic Idea Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 4 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Apr 21, 2011 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Aug 24, 2011 |
| Current Closing Date for Applications: | Aug 24, 2011 |
| Archive Date: | Sep 23, 2011 |
| Estimated Total Program Funding: | $2,560,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The Therapeutic Idea Award is designed to promote new ideas that are still in the early stages of development with the potential to yield highly impactful data and new avenues of investigation for novel therapeutics for ALS treatment. This mechanism supports conceptually innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancement in ALS therapeutics. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
301-682-5507
Email:help@cdmrp.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 89013 Full Announcement-1 -> fy11_alsrp_tia_pa_gg_ 21apr.pdf
Packages
| Agency Contact Information: | 301-682-5507 Email: help@cdmrp.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00049370 | Apr 21, 2011 | Aug 24, 2011 | View |
Package 1
Mandatory forms
89013 RR_SF424_1_2-1.2.pdf
89013 PerformanceSite_1_4-1.4.pdf
89013 RR_Budget-1.1.pdf
89013 RR_KeyPersonExpanded_1_2-1.2.pdf
Optional forms
89013 RR_SubawardBudget30-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
